Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C

Abstract

To study the clinical efficacy of PEG-Interferon alpha-2a combined with ribavirin in eldly chronic hepatitis. Forty patients with chronic hepatitis C were divided into treatment group and comparative group. The twenty eldly patients of treatment group receive peg-interferon alpha-2a 135-180 microg subcutaneous injection every week combined with ribavirin 600-1000 mg/d for 48 weeks, and twenty adult patients of control group receive peg-interferon 135-180 microg subcutaneous injection every week combined with ribavirin 800-1200 mg/d for 48 weeks. The rapid virological response (RVR) rate, early virological response (EVR) rate, end of treatment virological response (ETVR) rate, sustained virological response (SVR) rate, nonresponder rate, relapse rate and the side reaction was assessed, then to compare the differences between the two groups. The RVR rate, EVR rate, ETVR rate, SVR rate, nonresponder rate, relapse rate was 60%, 70%, 75%, 60%, 10%, 10% respectively, accordingly the rate in control group was 75%, 80%, 85%, 75%, 5%, 10%. The difference between the two group were not statistically significant (P > 0.05). Compared with the control group, the rate of neutropenia was higher in treatment group (P < 0.05). There was no difference between the two groups in influenza-like side effect, anemia, thrombocytopenia and gastrointestinal side reaction. The eldly patients with Chronic Hepatitis C using general dose peg-IFNalpha-2a combined with lower dose ribavirin can still obtain the similar efficiency and excellent tolerance when the basic diseases such as hypertension, diabetes and side effects were treated successfully.